Lawsuit Over Hydrogel Implant Targets Monitoring
Urology and oncology clinics should review verification protocols for implanted spacers to manage potential liability.
Updated on Oct. 21, 2026 in Healthcare
A Pennsylvania couple has filed a lawsuit in Massachusetts Superior Court alleging that a Boston Scientific SpaceOAR Vue hydrogel implant caused severe tissue damage. The complaint claims the device infiltrated the patient's rectal wall during prostate cancer treatment, leading to a permanent colostomy and the need for a urinary catheter.
Why it matters
The case highlights potential liability risks for providers and manufacturers regarding procedural warnings and the monitoring of hydrogel placement during radiation therapy. Operators in the urology and oncology space must weigh the operational implications of patient safety monitoring protocols following the use of implanted spacer devices.
The lawsuit centers on the SpaceOAR Vue, a device that received FDA clearance in July 2019 following Boston Scientific's 2018 acquisition of its developer, Augmenix. The original version of the hydrogel spacer was first cleared by the FDA in April 2015.
The players
Boston Scientific
A global developer and manufacturer of medical devices for interventional medical specialties including urology.
Daniel Patrick Marchio and Rose Marie Marchio
The plaintiffs who filed the complaint in Massachusetts Superior Court alleging injuries from the device.
The details
SpaceOAR hydrogels are injected between the prostate and rectum using ultrasound guidance to create physical distance and reduce radiation exposure to healthy tissue. The lawsuit alleges that Boston Scientific failed to sufficiently warn physicians to verify proper gel placement before beginning radiation treatment. The complaint claims radiation proceeded even after an MRI allegedly showed the material had infiltrated the rectal wall.
Timeline
April 2015: Original SpaceOAR device received FDA clearance.
2018: Boston Scientific acquired Augmenix.
July 2019: SpaceOAR Vue received FDA clearance.
October 14, 2026: Lawsuit filed in Massachusetts Superior Court.
Market Landscape
This litigation highlights the recurring legal challenges faced by medical device manufacturers regarding the adequacy of their warnings and procedural guidance. It follows a pattern of product liability claims where plaintiffs allege that standard-of-care protocols were insufficient given the risks of specific material placements.
Operators in oncology and urology should review their current protocols for verifying hydrogel placement before initiating radiation treatments. Clinics should consult with legal counsel to ensure that clinical procedures align with the latest manufacturer guidance and warning updates.
The takeaway
Clinicians should document all pre-radiation imaging and verification steps used to confirm the placement of temporary spacer implants. Maintaining rigorous compliance records is essential for mitigating liability in the event of unforeseen patient complications.
Further reading
For broader analysis on medical device compliance and risk, see Healthcare.
Source note: This article includes information reported by AboutLawsuits.
